Venus Concept (NASDAQ:VERO) Ltd. (NASDAQ: VERO) is a Canada-based medical aesthetic device company that designs, develops and commercializes minimally and noninvasive solutions for face and body rejuvenation. The company’s core product portfolio leverages proprietary technologies such as multi-polar radio frequency, pulsed electromagnetic fields and intense pulsed light to offer treatments for skin tightening, body contouring, wrinkle reduction and vascular lesion removal.
Among its flagship offerings are the Venus Legacy platform, which combines radio frequency and electromagnetic pulses for cellulite reduction and circumferential reduction, and the Venus Versa system, a multi-application device for facial revitalization, acne treatment, hair removal and photorejuvenation. Venus Concept continually invests in research and development to enhance treatment efficacy, patient comfort and practice efficiencies for aesthetic clinics.
The company markets its products worldwide through a combination of direct sales teams and distribution partners, serving markets across North America, Europe, Asia Pacific and the Middle East. Venus Concept’s global footprint includes offices in Toronto, New York and Munich, supported by a network of certified training centers and clinical educators to ensure optimal operator proficiency and patient outcomes.
Founded in 2010, Venus Concept transitioned into a publicly traded company in 2014 to fuel its expansion into new geographies and broaden its product suite. Under the leadership of Chief Executive Officer Orit Rahamim and Chief Financial Officer Dan Lee, the company has focused on strategic investments in technology innovation, clinical evidence generation and operational scalability to strengthen its position in the competitive medical aesthetics industry.
